MYD88 and primary central nervous system lymphoma: The high detection rates of MYD88 mutations in the CSF in PCNSL both at initial diagnosis and at relapse could be further improved by using ddPCR, thus becoming a potential useful tool in patients with lesions unsuitable for biopsy (68).